Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2). We developed a high sensitivity (HS) assay utilizing wild-type blocking polymerase chain reaction achieved via bridged and locked nucleic acids. We used this high sensitivity assay in combination with Sanger sequencing and next generation sequencing (NGS) and tested cellular DNA and cell-free DNA (cfDNA) from patients with CLL treated with the BTK inhibitor, ibrutinib. […]
Why not Stay in Touch…?
- John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing
- GTC research is being presented at ASCO 2020
- GTC was featured in the Orange County Business Journal again
- New Collaboration to Offer Liquid Biopsy Testing
- Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) Test
acute myeloid leukemia Adult AI AML apoptosis B-Cell Lymphoma beta 2-Microglobulin Biological Biological Processes Biomarkers bone marrow BTK Case Study chemotherapy Clinically relevant CLL Collaborations Congress Diseases DNA profiling enzyme inhibitors genetic profiling genomic testing Genomic Testing Cooperative gtc hematology ibrutinib Janus Kinase 2 Ki-67 Antigen leukemia liquid biopsy Lymphoid Malignancies Myeloid Malignancies ngs Non-Biological PLCγ2 press release Receptors resistance RNA sequencing Study Population Technology and Procedures Therapies Thrombopoietin Young Adult